Cargando…
A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report
BACKGROUND: Health services globally are struggling to manage the impact of COVID-19. The existing global disease burden related to opioid use is significant. Particularly challenging groups include older drug users who are more vulnerable to the effects of COVID-19. Increasing access to safe and ef...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366558/ https://www.ncbi.nlm.nih.gov/pubmed/32680520 http://dx.doi.org/10.1186/s12954-020-00394-z |
_version_ | 1783560243510247424 |
---|---|
author | Crowley, Des Delargy, Ide |
author_facet | Crowley, Des Delargy, Ide |
author_sort | Crowley, Des |
collection | PubMed |
description | BACKGROUND: Health services globally are struggling to manage the impact of COVID-19. The existing global disease burden related to opioid use is significant. Particularly challenging groups include older drug users who are more vulnerable to the effects of COVID-19. Increasing access to safe and effective opioid agonist treatment (OAT) and other harm reduction services during this pandemic is critical to reduce risk. In response to COVID-19, healthcare is increasingly being delivered by telephone and video consultation, and this report describes the development of a national model of remote care to eliminate waiting lists and increase access to OAT in Ireland. PURPOSE AND FINDINGS: The purpose of this initiative is to provide easy access to OAT by developing a model of remote assessment and ongoing care and eliminate existing national waiting lists. The Irish College of General Practitioners in conjunction with the National Health Service Executive office for Social Inclusion agreed a set of protocols to enable a system of remote consultation but still delivering OAT locally to people who use drugs. This model was targeted at OAT services with existing waiting lists due to a shortage of specialist medical staff. The model involves an initial telephone assessment with COVID-risk triage, a single-patient visit to local services to provide a point of care drug screen and complete necessary documentation and remote video assessment and ongoing management by a GP addiction specialist. A secure national electronic health link system allows for the safe and timely delivery of scripts to a designated local community pharmacy. CONCLUSION: The development of a remote model of healthcare delivery allows for the reduction in transmission risks associated with COVID-19, increases access to OAT, reduces waiting times and minimises barriers to services. An evaluation of this model is ongoing and will be reported once completed. Fast adaptation of OAT delivery is critical to ensure access to and continuity of service delivery and minimise risk to our staff, patients and community. Innovative models of remote healthcare delivery adapted during the COVID-19 crisis may inform and have important benefits to our health system into the future. |
format | Online Article Text |
id | pubmed-7366558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73665582020-07-20 A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report Crowley, Des Delargy, Ide Harm Reduct J Brief Report BACKGROUND: Health services globally are struggling to manage the impact of COVID-19. The existing global disease burden related to opioid use is significant. Particularly challenging groups include older drug users who are more vulnerable to the effects of COVID-19. Increasing access to safe and effective opioid agonist treatment (OAT) and other harm reduction services during this pandemic is critical to reduce risk. In response to COVID-19, healthcare is increasingly being delivered by telephone and video consultation, and this report describes the development of a national model of remote care to eliminate waiting lists and increase access to OAT in Ireland. PURPOSE AND FINDINGS: The purpose of this initiative is to provide easy access to OAT by developing a model of remote assessment and ongoing care and eliminate existing national waiting lists. The Irish College of General Practitioners in conjunction with the National Health Service Executive office for Social Inclusion agreed a set of protocols to enable a system of remote consultation but still delivering OAT locally to people who use drugs. This model was targeted at OAT services with existing waiting lists due to a shortage of specialist medical staff. The model involves an initial telephone assessment with COVID-risk triage, a single-patient visit to local services to provide a point of care drug screen and complete necessary documentation and remote video assessment and ongoing management by a GP addiction specialist. A secure national electronic health link system allows for the safe and timely delivery of scripts to a designated local community pharmacy. CONCLUSION: The development of a remote model of healthcare delivery allows for the reduction in transmission risks associated with COVID-19, increases access to OAT, reduces waiting times and minimises barriers to services. An evaluation of this model is ongoing and will be reported once completed. Fast adaptation of OAT delivery is critical to ensure access to and continuity of service delivery and minimise risk to our staff, patients and community. Innovative models of remote healthcare delivery adapted during the COVID-19 crisis may inform and have important benefits to our health system into the future. BioMed Central 2020-07-17 /pmc/articles/PMC7366558/ /pubmed/32680520 http://dx.doi.org/10.1186/s12954-020-00394-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Brief Report Crowley, Des Delargy, Ide A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report |
title | A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report |
title_full | A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report |
title_fullStr | A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report |
title_full_unstemmed | A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report |
title_short | A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report |
title_sort | national model of remote care for assessing and providing opioid agonist treatment during the covid-19 pandemic: a report |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366558/ https://www.ncbi.nlm.nih.gov/pubmed/32680520 http://dx.doi.org/10.1186/s12954-020-00394-z |
work_keys_str_mv | AT crowleydes anationalmodelofremotecareforassessingandprovidingopioidagonisttreatmentduringthecovid19pandemicareport AT delargyide anationalmodelofremotecareforassessingandprovidingopioidagonisttreatmentduringthecovid19pandemicareport AT crowleydes nationalmodelofremotecareforassessingandprovidingopioidagonisttreatmentduringthecovid19pandemicareport AT delargyide nationalmodelofremotecareforassessingandprovidingopioidagonisttreatmentduringthecovid19pandemicareport |